Context Therapeutics, Inc. (CNTX)

NASDAQ: CNTX · IEX Real-Time Price · USD
1.31
-0.07 (-5.07%)
At close: Dec 5, 2022 4:00 PM
1.33
+0.02 (1.53%)
After-hours: Dec 5, 2022 4:55 PM EST
-5.07%
Market Cap 22.03M
Revenue (ttm) n/a
Net Income (ttm) -14.37M
Shares Out 15.97M
EPS (ttm) -1.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 59,705
Open 1.31
Previous Close 1.38
Day's Range 1.31 - 1.36
52-Week Range 0.95 - 7.65
Beta n/a
Analysts Buy
Price Target 6.12 (+367.2%)
Earnings Date Dec 1, 2022

About CNTX

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is ... [Read more]

Industry Pharmaceuticals
IPO Date Oct 20, 2021
Employees 2
Stock Exchange NASDAQ
Ticker Symbol CNTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CNTX stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 367.18% from the latest price.

Price Target
$6.12
(367.18% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Sol...

CTIM-76 named as lead candidate to target Claudin 6 positive cancers

6 days ago - GlobeNewsWire

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metas...

2 weeks ago - GlobeNewsWire

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Company reports preliminary ONA-XR data from two ongoing Phase 2 trials

3 weeks ago - GlobeNewsWire

Context Therapeutics to Participate in the ThinkEquity Conference

Philadelphia, Pennsylvania--(Newsfile Corp. - October 20, 2022) - Context Therapeutics Inc. (NASDAQ: CNTX) ("Context" or the "Company"), a women's oncology company developing novel treatments for breast...

1 month ago - Newsfile Corp

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 c...

2 months ago - GlobeNewsWire

Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing novel treatments for breast and gynecologica...

2 months ago - GlobeNewsWire

Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results

Announced new clinical trial collaboration with Menarini Group to evaluate ONA-XR plus elacestrant in metastatic breast cancer

3 months ago - GlobeNewsWire

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ON...

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE...

4 months ago - PRNewsWire

Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting

6 months ago - GlobeNewsWire

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Associ...

Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models

7 months ago - GlobeNewsWire

Context Therapeutics® to Participate in Two April 2022 Investor Conferences

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments ...

7 months ago - GlobeNewsWire

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

Investor R&D event on April 13 th to highlight new preclinical data to be presented at AACR Annual Meeting

8 months ago - GlobeNewsWire

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer R...

Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET

8 months ago - GlobeNewsWire

Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum

PHILADELPHIA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments f...

9 months ago - GlobeNewsWire

Context Therapeutics® Strengthens Research & Development Team

Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D

11 months ago - GlobeNewsWire

Context Therapeutics® to Participate in Two January 2022 Investor Conferences

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments f...

11 months ago - GlobeNewsWire

CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring Today

Context Therapeutics (CNTX) stock is rising higher on Friday thanks to results from a Phase 0 breast cancer clinical trial. The post CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Th...

11 months ago - InvestorPlace

Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer

Context Therapeutics Inc (NASDAQ: CNTX) posted data from the window-of-opportunity trial of onapristone extended-release (ONA-XR) in postmenopausal patients with progesterone receptor-positive (PR+) ear...

11 months ago - Benzinga

Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Sy...

Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer

11 months ago - GlobeNewsWire

Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement

PHILADELPHIA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women's oncology company developing small molecule and immunotherapy...

11 months ago - GlobeNewsWire

Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results

Entered into $31.25 million Private Placement Agreement

1 year ago - GlobeNewsWire

Context Therapeutics Shares Drop After Raising $31M Via Equity

Newly listed Context Therapeutics Inc (NASDAQ: CNTX) has announced a private placement of $31.25 million. The placement includes 5 million shares together with warrants to purchase 5 million shares.

1 year ago - Benzinga

Context Therapeutics Inc. Announces $31.25 Million Private Placement

PHILADELPHIA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women's oncology company developing small molecule and immunotherapy...

1 year ago - GlobeNewsWire

Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium

Primary results from ONAWA (SOLTI-1802) trial of ONA-XR in early breast cancer to be presented in addition to updates from ongoing clinical trials of ONA-XR in metastatic breast cancer Primary results f...

1 year ago - GlobeNewsWire

Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer

Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO

1 year ago - GlobeNewsWire